Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT03787732
Other study ID # IRB# 181690
Secondary ID
Status Completed
Phase Phase 4
First received
Last updated
Start date February 1, 2019
Est. completion date June 21, 2021

Study information

Verified date August 2021
Source Vanderbilt University Medical Center
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Complications are common during tracheal intubation of critically ill patients. Nearly one in five patients undergoing intubation in the intensive care unit experiences cardiovascular collapse, defined as severe hypotension, vasopressor administration, cardiac arrest or death. Cardiovascular collapse during intubation is associated with increased resource utilization and decreased survival. Administration of 500 mL of intravenous crystalloid solution beginning prior to induction may prevent cardiovascular collapse. The only prior trial examining fluid bolus administration during intubation found no effect on cardiovascular collapse or clinical outcomes overall, but a hypothesis-generating subgroup analysis suggested potential benefit to fluid bolus administration among patients receiving positive pressure ventilation between induction and laryngoscopy. Therefore, we propose a randomized trial comparing fluid bolus administration versus none with regard to cardiovascular collapse among critically adults undergoing intubation with positive pressure ventilation between induction and laryngoscopy.


Description:

The PREPARE II trial is a prospective, parallel group, pragmatic, randomized trial comparing the effect of a preintubation fluid bolus to no preintubation fluid bolus on the incidence of cardiovascular collapse during and after endotracheal intubation in critically ill adults. Patients admitted to the study units who are deemed by their clinical team to require intubation and fulfill inclusion criteria without meeting exclusion criteria will be randomized 1:1 to receive either an intravenous fluid bolus or no intravenous fluid bolus. All other decisions regarding airway management will remain at the discretion of the treating provider. Conduct of the trial will be overseen by a Data Safety Monitoring Board. An interim analysis will be performed after the enrollment of 375 patients. The analysis of the trial will be conducted in accordance with a pre-specified statistical analysis plan, which will be submitted for publication or made publicly available prior to the conclusion of enrollment. The primary outcome is cardiovascular collapse - a composite endpoint defined as one or more of the following: 1. Death within 1 hour of intubation 2. Cardiac arrest within 1 hour of intubation 3. New systolic blood pressure < 65 mmHg between induction and 2 minutes after completion of intubation 4. New or increased vasopressor receipt between induction and 2 minutes after completion of intubation The secondary outcome is 28-day in-hospital mortality


Recruitment information / eligibility

Status Completed
Enrollment 1067
Est. completion date June 21, 2021
Est. primary completion date May 24, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patient is undergoing endotracheal intubation in a participating unit 2. Planned operator is a provider expected to routinely perform endotracheal intubation in the participating unit 3. Patient is at least 18 years of age 4. Administration of sedation is planned (with or without neuromuscular blockade) 5. Positive pressure ventilation between induction and laryngoscopy is planned (e.g., non-invasive ventilation or bag-mask ventilation) Exclusion Criteria: 1. Prisoners 2. Pregnant patients 3. Urgency of intubation precludes safe performance of study procedures 4. Operator feels administration of a fluid bolus is indicated or contraindicated for the safe performance of the procedure

Study Design


Intervention

Drug:
Fluid Bolus
500 milliliters of an intravenous crystalloid solution of the operator's choosing
Other:
No Fluid Bolus
No additional intravenous crystalloid administration initiated between randomization and two minutes after completion of endotracheal intubation

Locations

Country Name City State
United States University of Alabama at Birmingham Birmingham Alabama
United States Lahey Hospital & Medical Center Burlington Massachusetts
United States University of Mississippi Medical Center Jackson Mississippi
United States Hennepin County Medical Center Minneapolis Minnesota
United States Vanderbilt University Medical Center Nashville Tennessee
United States Louisiana State University School of Medicine New Orleans Louisiana
United States Ochsner Medical Center | Ochsner Health System New Orleans Louisiana
United States Oregon Health & Science University Portland Oregon
United States University of Washington Seattle Washington
United States Baylor Scott & White Medical Center - Temple Temple Texas
United States Wake Forest Baptist Medical Center Winston-Salem North Carolina

Sponsors (1)

Lead Sponsor Collaborator
Vanderbilt University Medical Center

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Other New systolic blood pressure < 65 mmHg between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other New or increased vasopressor between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other Cardiac arrest within 1 hour of intubation 1 hour
Other Death within 1 hour of intubation 1 hour
Other Lowest systolic blood pressure between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other Change in systolic blood pressure from induction to lowest systolic blood pressure between induction and 2 minutes following procedure
Other Ventilator-free days 28 days
Other ICU-free days 28 days
Other Lowest oxygen saturation Lowest arterial oxygen saturation between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other Incidence of hypoxemia Incidence of oxygen saturation < 90% between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other Incidence of severe hypoxemia Incidence of oxygen saturation < 80% between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other Oxygen saturation at 24 hours after intubation 24 hours
Other Fraction of inspired oxygen at 24 hours after intubation 24 hours
Other Positive end expiratory pressure at 24 hours after intubation 24 hours
Other Systolic blood pressure at 24 hours after intubation 24 hours
Other Additional intravenous fluids initiated between induction and 2 minutes after intubation from induction to 2 minutes following tracheal intubation
Other Time from induction to successful intubation Duration of procedure (minutes)
Other Cormack-Lehane grade of glottic view on first attempt Duration of procedure (minutes)
Other Difficulty of intubation Operator-reported difficulty of intubation on a three-point ordinal scale of: easy, moderate, or difficult. Duration of procedure (minutes)
Other Incidence of successful intubation on the first laryngoscopy attempt Duration of procedure (minutes)
Other Number of laryngoscopy attempts Duration of procedure (minutes)
Other Need for additional airway equipment or a second operator Duration of procedure (minutes)
Primary Cardiovascular collapse A composite endpoint defined as one or more of the following
New systolic blood pressure < 65 mmHg between induction and 2 minutes after intubation
New or increased vasopressor between induction and 2 minutes after intubation
Cardiac arrest within 1 hour of intubation
Death within 1 hour of intubation
1 hour
Secondary 28-day in-hospital mortality 28 days
See also
  Status Clinical Trial Phase
Recruiting NCT05144633 - Blue Protocol and Eko Artificial Intelligence Are Best (BEA-BEST)
Completed NCT04534569 - Expert Panel Statement for the Respiratory Management of COVID-19 Related Acute Respiratory Failure (C-ARF)
Recruiting NCT03021902 - Nutrition and Exercise in Critical Illness Phase 2
Completed NCT02902146 - Bougie Use in Emergency Airway Management N/A
Completed NCT02901158 - Esophageal Manometry in Mechanically Ventilated Patients
Completed NCT02236559 - High Flow Therapy for the Treatment of Respiratory Failure in the ED N/A
Recruiting NCT02056093 - Comparison of Proportional Assist Ventilation And Neurally Adjusted Ventilator Assist N/A
Not yet recruiting NCT01668368 - Goal Directed Mechanical Ventilation Aimed at Optimal Lung Compliance N/A
Terminated NCT01083277 - Variable Ventilation During Acute Respiratory Failure N/A
Completed NCT01462279 - Effect of Thiamine on Oxygen Utilization (VO2) in Critical Illness N/A
Completed NCT01114022 - Prevention Inhalation of Bacterial by Using Endotracheal Tube Balloon Polyvinyl Chloride or Polyurethane N/A
Active, not recruiting NCT01058421 - Treatment of Critical Illness Polyneuromyopathy Phase 2
Completed NCT00252616 - Timing of Target Enteral Feeding in the Mechanically Ventilated Patient Phase 2/Phase 3
Recruiting NCT04098094 - Outcomes of RV Dysfunction in Acute Exacerbation of Chronic Respiratory Diseases
Recruiting NCT06051292 - Decremental Esophageal Catheter Filling Volume Titration For Transpulmonary Pressure Measurement N/A
Completed NCT04601090 - Survival Rates and Longterm Outcomes After COVID-19
Recruiting NCT05423301 - Global Physiotherapy in ICU Patients With High Risk Extubation Failure N/A
Completed NCT02447692 - Proportional Assist Ventilation for Minimizing the Duration of Mechanical Ventilation: The PROMIZING Study N/A
Completed NCT04016480 - HFNC During Bronchoscopy for Bronchoalveolar Lavage N/A
Completed NCT04507425 - High Flow Nasal Cannula With Noninvasive Ventilation N/A